Last reviewed · How we verify
Tolvaptan Tablets
Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor.
Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor. Used for Chronic heart failure, Hyponatremia.
At a glance
| Generic name | Tolvaptan Tablets |
|---|---|
| Sponsor | Institute of Liver and Biliary Sciences, India |
| Drug class | Vasopressin receptor antagonist |
| Target | V2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the V2 receptor, tolvaptan reduces water reabsorption in the kidneys, leading to increased urine production and decreased fluid volume in the body. This mechanism is particularly useful in treating conditions such as hyponatremia and heart failure.
Approved indications
- Chronic heart failure
- Hyponatremia
Common side effects
- Headache
- Diarrhea
- Fatigue
Key clinical trials
- A Study to See Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD) (PHASE3)
- Bempedoic Acid Therapy for Polycystic Kidney Disease (PHASE2)
- A Study of HRS-9057 in Patients With Heart Failure and Volume Overload (PHASE1)
- Single Dose of 7.5mg Tolvaptan Phase I Clinical Trial Protocol (PHASE1)
- a Phase I PK Study in Healthy Male Subjects. 2 Groups of Healthy Male Subjects (PHASE1)
- Phase I Study Multi Dose of 7.5mg Tolvaptan in Health Male (PHASE1)
- Samsca PMS in ADPKD Patients
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tolvaptan Tablets CI brief — competitive landscape report
- Tolvaptan Tablets updates RSS · CI watch RSS
- Institute of Liver and Biliary Sciences, India portfolio CI